Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Euro Surveill ; 21(1)2016.
Article in English | MEDLINE | ID: mdl-26767388

ABSTRACT

A German businessman developed acute watery diarrhoea after a three-day trip to the Philippines. He was admitted with severe hypotension and acute renal failure, but recovered with rapid rehydration. Vibrio cholerae O1 serotype Ogawa was isolated. Physicians need to be aware of endemic cholera in Asia including the Philippines and consider this in their pre-travel advice.


Subject(s)
Cholera/diagnosis , Diarrhea/etiology , Renal Insufficiency/complications , Vibrio cholerae O1/isolation & purification , Cholera/microbiology , Cholera/therapy , Feces/microbiology , Genotype , Germany , Humans , Infusions, Intravenous , Male , Middle Aged , Philippines , Real-Time Polymerase Chain Reaction , Travel , Treatment Outcome , Vibrio cholerae O1/genetics
2.
J Antimicrob Chemother ; 69(9): 2361-8, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24855123

ABSTRACT

OBJECTIVES: Co-trimoxazole (trimethoprim/sulfamethoxazole) is clinically valuable in treating skin and soft tissue infections (SSTIs) caused by community-associated methicillin-resistant Staphylococcus aureus (MRSA). The genetic basis of emerging trimethoprim/sulfamethoxazole resistance in S. aureus from Africa is unknown. Such knowledge is essential to anticipate its further spread. We investigated the molecular epidemiology of trimethoprim resistance in S. aureus collected in and imported from Africa. METHODS: Five hundred and ninety-eight human S. aureus isolates collected at five locations across sub-Saharan Africa [Gabon, Namibia, Nigeria (two) and Tanzania] and 47 isolates from travellers treated at six clinics in Europe because of SSTIs on return from Africa were tested for susceptibility to trimethoprim, sulfamethoxazole and trimethoprim/sulfamethoxazole, screened for genes mediating trimethoprim resistance in staphylococci [dfrA (dfrS1), dfrB, dfrG and dfrK] and assigned to spa genotypes and clonal complexes. RESULTS: In 313 clinical and 285 colonizing S. aureus from Africa, 54% of isolates were resistant to trimethoprim, 21% to sulfamethoxazole and 19% to trimethoprim/sulfamethoxazole. We found that 94% of trimethoprim resistance was mediated by the dfrG gene. Of the 47 S. aureus isolates from travellers with SSTIs, 27 (57%) were trimethoprim resistant and carried dfrG. Markers of trimethoprim resistance other than dfrG were rare. The presence of dfrG genes in S. aureus was neither geographically nor clonally restricted. CONCLUSIONS: dfrG, previously perceived to be an uncommon cause of trimethoprim resistance in human S. aureus, is widespread in Africa and abundant in imported S. aureus from ill returning travellers. These findings may foreshadow the loss of trimethoprim/sulfamethoxazole for the empirical treatment of SSTIs caused by community-associated MRSA.


Subject(s)
Anti-Bacterial Agents/pharmacology , Genes, Bacterial , Staphylococcal Infections/microbiology , Staphylococcal Infections/transmission , Staphylococcus aureus/drug effects , Staphylococcus aureus/genetics , Trimethoprim Resistance , Adult , Africa South of the Sahara , DNA, Bacterial/genetics , Europe , Humans , Microbial Sensitivity Tests , Molecular Epidemiology , Molecular Typing , Soft Tissue Infections/microbiology , Soft Tissue Infections/transmission , Staphylococcus aureus/classification , Staphylococcus aureus/isolation & purification , Travel
3.
J Travel Med ; 25(1)2018 01 01.
Article in English | MEDLINE | ID: mdl-29688492

ABSTRACT

Background: The study goal was to assess and compare adverse events (AE) of current vaccinations for travelers under 'real-life conditions'. Methods: A prospective observational online questionnaire study was performed from May 2015 till April 2016 in a travel clinic in Germany. Online questionnaire links were sent 1 week after the first vaccination date. Severity was rated on a scale from 1 to 5 (minor to very severe AE). Results: Of 1357 vaccinees 781 (57.6%) responded to the questionnaire, corresponding to 1415 vaccinations (1-7 simultaneous vaccinations). Responders were more often female (f:m = 1.29:1). Main age groups were 20-29 years old (36.1%). Most frequent vaccinations were against rabies (277; chick embryo cell vaccine (CEC): 97, human diploid cell vaccine (HDC): 180), yellow fever (250), typhoid fever (198), meningococcal meningitis (126) and Japanese encephalitis (104). A total of 217 vaccinees (27.8%) reported AE; 82 (10.5%) rated AE as more severe (grade 3: 61, grade 4: 18, grade 5: 3). No life-threatening AE was reported. Of 157 systemic AE the most frequent were: fatigue (75), headaches (46) and pyrexia (31). Of 94 local AE most frequently reported were pain (66), myalgia (25) and swelling (12). AE after single vaccinations were more often associated with rabies vaccine (OR 2.2; 1.2-4.2). AE increased with the number of simultaneous vaccinations (single vaccination: 24.1%, 88/365; 2 vaccinations: 26.6%, 73/274, ≥3 vaccinations: 39.4%, 56/142, χ2 = 12.24, P = 0.002, CCorr = 0.18), but more severe AE showed no association with the number of vaccinations (χ2 = 5.55, P = 0.06, CCorr = 0.12). Conclusions: Single and simultaneous vaccinations were overall well tolerated. AE were reported more frequently with rabies vaccinations in single vaccinations. Increased numbers of simultaneous vaccinations led to some incremental AE but not to more severe AE. Simultaneous vaccinations should be encouraged to reduce missed opportunities for immunizations.


Subject(s)
Rabies Vaccines/adverse effects , Travel , Vaccination/adverse effects , Vaccines, Combined/adverse effects , Adolescent , Adult , Aged , Animals , Chick Embryo , Child , Female , Germany , Humans , Internet , Male , Middle Aged , Prospective Studies , Surveys and Questionnaires , Young Adult
4.
Urology ; 73(1): 209.e1-3, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18384864

ABSTRACT

Dirofilariasis due to Dirofilaria repens is a rare anthropozoonotic disease, with dogs and cats being the definite hosts for this parasite. This worm is transmitted by various species of mosquitoes and usually presents as a subcutaneous nodule. Human cases have been reported from all around the Mediterranean, Eastern Europe, and Central and Southern Asia. In the present case involving a 28-year-old patient of Tunisian origin, infection manifested as a nodule in the left epididymis. In the context of increasing international travel and migration, dirofilariasis is a diagnosis that should be kept in mind when treating patients who have spent some time in endemic areas and present with unclear subcutaneous or scrotal nodules.


Subject(s)
Dirofilariasis/diagnosis , Genital Neoplasms, Male/diagnosis , Scrotum , Adult , Diagnosis, Differential , Humans , Male
5.
J Antimicrob Chemother ; 59(4): 767-71, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17293369

ABSTRACT

OBJECTIVES: The aim of this study is to evaluate the susceptibilities of Candida spp. to the common antifungal agents in a German university hospital. Since quick results of in vitro testing are desirable, Etest and the CLSI broth microdilution (BMD) method (reference method) were compared, focusing on the validity of early readings. METHODS: A total of 512 Candida spp. isolates, including 174 from primarily sterile sites, were collected in the clinical routine. The yeasts were differentiated by CHROMagar and verified by API 20C AUX if necessary. In vitro susceptibilities to amphotericin B, flucytosine, fluconazole, voriconazole and caspofungin were determined using the BMD method described in the CLSI (formerly NCCLS) M27-A2 document and Etest. MICs were noted after 24 and 48 h of incubation. RESULTS: The most frequently isolated species was Candida albicans. Among the non-albicans species, Candida glabrata was the most prevalent, followed by Candida tropicalis, Candida parapsilosis and Candida krusei. MICs (mg/L) at which 90% of the strains were inhibited were 1 for amphotericin B, 32 for flucytosine, 8 for fluconazole, 0.25 for voriconazole and 1 for caspofungin. Susceptibility to fluconazole was 85.0% for C. glabrata and 5.3% for C. krusei, almost all other isolates were susceptible in over 90% except very rare species. The 48 h MIC values of Etest and BMD were in agreement (no more than 2 log(2) dilutions) in 88.7% to 98.1% with categorical agreement rates of 91.6% to 98.2%, depending on the antifungal agent. Comparison of the 24 h MICs of both BMD and Etest with the 48 h MICs of the reference method showed categorical agreement in 94.9% to 99.2%. For caspofungin, however, a comparison of the categorical agreement was not possible due to the lack of interpretive breakpoints. The order of frequency and the resistance patterns of the isolates from primarily sterile sites and those of isolates from non-sterile sites did not differ. CONCLUSIONS: No alarming resistances against the agents tested were found; however, owing to the relatively high frequency of C. glabrata with elevated fluconazole MICs, this species and, to a certain extent, C. krusei must be taken into consideration when choosing antifungal agents for calculated therapy. Etest is a reliable method for the susceptibility testing of Candida spp. and the 24 h readings of both Etest and BMD can serve as helpful preliminary results in most cases.


Subject(s)
Antifungal Agents/pharmacology , Candida/drug effects , Drug Resistance, Fungal , Germany , Hospitals, University , Microbial Sensitivity Tests , Reproducibility of Results
SELECTION OF CITATIONS
SEARCH DETAIL